S-ethylisothiouronium Suppository for Uterine Hypercontractility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for abnormal uterine bleeding and dysmenorrhea often have limited efficacy and are associated with significant side effects, contraindications, and impact on fertility, particularly for women who wish to conceive.
Innovation Solution
Administration of a pharmaceutical composition containing S-ethylisothiouronium diethylphosphate, which is formulated as a vaginal suppository, effectively reduces and eliminates uterine cramping and pelvic pain associated with dysmenorrhea, and normalizes menstrual cycles in women with abnormal uterine bleeding, with minimal side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current non-surgical therapies (oral contraceptives, GnRH agonists, progestins) are used to treat abnormal uterine bleeding, then bleeding is reduced, but efficacy is limited and other steroid hormone-dependent tissues (breast, bone) are significantly impacted
Solution Approach 1:
The patent applies local quality by developing a vaginal suppository formulation that delivers the active compound directly to the uterine tissue. This localized delivery system concentrates the therapeutic effect at the target site (uterus) while minimizing systemic exposure to steroid hormone-dependent tissues such as breast and bone, thereby resolving the contradiction between effective bleeding control and reduced side effects on other tissues
Solution Approach 2:
The vaginal suppository acts as an intermediary delivery system between the active compound and the uterine tissue. This intermediary formulation enables targeted drug delivery to the uterus through the vaginal mucosa, achieving therapeutic effects locally while avoiding the widespread systemic distribution that causes harmful effects on other steroid-sensitive tissues
2Reliability
If surgical therapies (hysterectomy, myomectomy, endometrial ablation) are used to treat abnormal uterine bleeding, then bleeding is effectively controlled, but anesthesia is required and significant morbidity and mortality risks occur
Solution Approach 1:
The vaginal suppository represents a disposable, non-invasive therapeutic alternative to permanent surgical interventions. This temporary, locally-administered formulation provides effective bleeding control without the need for anesthesia or surgical procedures, thereby eliminating the associated morbidity and mortality risks while maintaining therapeutic efficacy
Solution Approach 2:
The patent extracts the essential therapeutic function from invasive surgical procedures by developing a pharmacological formulation that achieves bleeding control through local vaginal administration. This extraction of the core therapeutic effect from the harmful surgical context provides an effective alternative that eliminates anesthesia requirements and surgical risks
3Object-affected harmful factors
If NSAIDs are used to treat dysmenorrhea, then uterine cramps are reduced, but gastrointestinal disorders, renal dysfunction, and central nervous system disturbances occur
Solution Approach 1:
The vaginal suppository formulation serves as an intermediary delivery system that transports the active compound directly to the uterine tissue, bypassing the gastrointestinal tract and renal systems. This localized delivery mechanism achieves cramp relief while avoiding the gastrointestinal disorders, renal dysfunction, and central nervous system disturbances associated with oral NSAID administration
4Object-affected harmful factors
If oral contraceptives are used to treat primary dysmenorrhea, then cramps are reduced, but numerous contraindications exist and regular intake is required
Solution Approach 1:
The vaginal suppository provides localized therapy directly at the uterus, eliminating the need for systemic hormonal suppression required by oral contraceptives. This local delivery approach reduces cramps without the numerous contraindications associated with oral contraceptives and offers greater usage flexibility, allowing women to treat symptoms without committing to regular monthly intake cycles
Solution Approach 2:
Instead of using systemic hormonal suppression (oral contraceptives) to treat dysmenorrhea, the patent inverts the approach by using local vaginal administration of an active compound that directly targets uterine tissue. This inverted strategy achieves cramp relief through local action rather than systemic hormonal manipulation, thereby eliminating contraindications and improving usage flexibility
Data Source
AI summary
The present invention relates to methods for treating uterine hypercontractility disorders. in particular, the present invention relates to methods for treating abnormal uterine bleeding and dysmenorrhea comprising administering to women suffering from such disorders a pharmaceutical composition comprising an S-alkylisothiouronium derivative.